Patents Examined by Marcela M. Cordero Garcia
  • Patent number: 10624968
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 21, 2020
    Assignee: BICYCLERD LIMITED
    Inventors: Gavin Bennett, Daniel Paul Teufel
  • Patent number: 10624945
    Abstract: A method of treatment of pain in a person with a D peptide chemokine receptor antagonist (CRA), and a pharmaceutically acceptable carrier is disclosed. Because chemokines desensitize opiate receptors and enhance the perception of pain said D-peptide CRA, given with a suboptimal dose of an opioid, such as morphine, will restore opioid analgesic efficacy by blocking the cognate chemokine ligand from binding to its receptor and desensitizing the opioid receptor. This strategy of combining a suboptimal dose of morphine with a CRA enhances the potency of morphine, permitting use of lower doses of morphine to obtain equivalent and near maximal analgesia. Lower morphine (opioid) doses have less risk of adverse effects, and potentially also of development of tolerance and dependence.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 21, 2020
    Assignee: Creative Bio-Peptides Inc.
    Inventor: Michael R. Ruff
  • Patent number: 10620184
    Abstract: Methods are provided for quantifying the cyclin-dependent kinase inhibitor 2A protein (p16) p16 protein directly in biological samples that have been fixed in formalin by SRM/MRM mass spectrometry. A protein sample is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and the p16 protein is quantitated in the resulting sample by quantitating in the protein sample at least one fragment peptide from p16. Peptides can be quantitated in modified or unmodified form. An example of a modified form of a p16 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: April 14, 2020
    Assignee: NantOmics, LLC
    Inventors: David B. Krizman, Todd Hembrough, Eunkyung An
  • Patent number: 10588844
    Abstract: The present disclosure provides oleanoyl tripeptide to prevent skin aging. More specifically the invention discloses the anti-collagenase, anti-elastase, enhancement of TGF-? secretion in fibroblasts, UV protection, oxidative stress protection, and other properties of the oleanoyl-KVK tripeptide which aids in preventing skin aging.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: March 17, 2020
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Rajendran Ramanujam
  • Patent number: 10591478
    Abstract: The present invention is directed towards methods for treating non-alcoholic fatty liver disease (NAFLD) in a patient and determining prognosis of NAFLD in a patient.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: March 17, 2020
    Assignee: Roseman University of Health Sciences
    Inventors: Thuc T. Le, Yasuyo Urasaki, Ronald R. Fiscus
  • Patent number: 10588942
    Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 17, 2020
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Li Tang, Darrell J. Irvine
  • Patent number: 10588950
    Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: March 17, 2020
    Assignee: PFIZER INC.
    Inventors: Debra D. Pittman, Rodney M. Camire, Joachim Fruebis
  • Patent number: 10584160
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 10, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
  • Patent number: 10576126
    Abstract: [Problem] To provide a highly safe and efficacious antitumor agent that is derived from probiotics. [Solution] The present invention relates to an antitumor agent comprising a compound represented by formula (1) or a complex thereof as an active ingredient. In formula (1): R1 represents a hydrogen atom or a hydroxymethyl group; R2 represents a hydrogen atom, a methyl group or a hydroxymethyl group; and R3, R4 and R5 each independently represent a methyl group, an N5-(trans-5-hydroxy-3-methylpent-2-enoyl) group, an N5-(cis-5-hydroxy-3-methylpent-2-enoyl) group or an N5-(trans-4-carboxy-3-methylpent-2-enoyl) group. According to the present invention, a highly safe and efficacious antitumor agent can be provided.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: March 3, 2020
    Assignee: National University Corporation Asahikawa Medical University
    Inventors: Mikihiro Fujiya, Hiroaki Konishi, Kentaro Moriichi
  • Patent number: 10570178
    Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 25, 2020
    Assignee: AVELAS BIOSCIENCES, INC.
    Inventors: Jesus Gonzalez, Junjie Liu
  • Patent number: 10561711
    Abstract: The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 18, 2020
    Assignee: THERMALIN, INC.
    Inventors: Richard William Berenson, Bruce Frank, Michael A. Weiss, Thomas Hattier, Gregory Dubé, Zhiqiang Chen
  • Patent number: 10561702
    Abstract: The present invention relates to a novel use of proline containing dipeptides for the prevention and/or treatment of skin conditions associated with altered, damaged or malfunctioning sebaceous glands.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 18, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Remo Campiche, Dominik Imfeld, Eileen Jackson, Eliane Ursula Wandeler
  • Patent number: 10557128
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Grant
    Filed: March 24, 2018
    Date of Patent: February 11, 2020
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Venkatesh Chelvam, Youngsoon Kim, Sumith A. Kularatne
  • Patent number: 10543250
    Abstract: Antimicrobial peptides, compositions and methods are described that are useful for treating infectious diseases, including those caused by drug resistant Gram-negative bacteria (e.g., Pseudomonas and Acinetobacter) and parasite-caused diseases such as malaria. The peptides include a modular kinocidin gamma-core connected directly, or through a short spacer, to a kinocidin C-terminal alpha-helix.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: January 28, 2020
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventor: Michael R. Yeaman
  • Patent number: 10538554
    Abstract: Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: January 21, 2020
    Assignee: VIRAMATIX SDN BHD
    Inventor: Mohamed Rajik Mohamed Ibrahim
  • Patent number: 10538784
    Abstract: Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: January 21, 2020
    Assignee: MOLECULAR TRANSFER, INC.
    Inventors: Gulilat Gebeyehu, Joel Jessee
  • Patent number: 10538558
    Abstract: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCR??-CD3??-CD3??-?? signaling complex. Yet more specifically, the peptides act on the TCR?/CD3??/?? signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 21, 2020
    Assignee: SIGNABLOK, INC
    Inventor: Alexander B. Sigalov
  • Patent number: 10537608
    Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 21, 2020
    Assignee: ALLYSTA PHARMACEUTICALS, INC.
    Inventor: Henry Hsu
  • Patent number: 10534002
    Abstract: Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: January 14, 2020
    Assignee: Biodesix, Inc.
    Inventors: Paul Edward Kearney, Xiao-Jun Li, Clive Hayward, Miguel Dominguez Geeraerts
  • Patent number: 10532084
    Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 14, 2020
    Assignee: EYEBIO KOREA
    Inventor: Jae Wook Yang